2026年2月8日结束的禁闭协议 限制Kymera治疗师内部人出售股份 目的是防止股价波动 A lock-up agreement ending Feb. 8, 2026, restricts Kymera Therapeutics' insiders from selling shares, aiming to prevent stock volatility post-offering.

将于2026年2月8日结束的Kymera治疗系统监管协议限制董事和官员在未经承保人批准的情况下出售或转让股票、期权、授权证或可兑换证券。 A lock-up agreement for Kymera Therapeutics, set to end on February 8, 2026, restricts directors and officers from selling or transferring shares, options, warrants, or convertible securities without underwriter approval. 从2025年12月9日开始的61天限制还禁止提交登记申报表或订立转移股票所有权风险的安排。 The 61-day restriction, beginning December 9, 2025, also bars filing registration statements or entering into arrangements that shift stock ownership risks. 豁免适用于与Atlas风险伙伴公司、Baker Bros.顾问公司和BVF伙伴公司有关联的董事,允许他们就资金持有的证券采取行动,这可能间接影响股票价格。 Exemptions apply to directors affiliated with Atlas Venture Partners, Baker Bros. Advisors LP, and BVF Partners L.P., allowing them to act on fund-held securities, which could indirectly impact the stock price. 该措施旨在防止在公开报价后市场波动。 The measure aims to prevent market volatility after a public offering.